BRECADD IS NON‐INFERIOR TO EBEACOPP IN PATIENTS WITH ADVANCED STAGE CLASSICAL HODGKIN LYMPHOMA: EFFICACY RESULTS OF THE GHSG PHASE III HD21 TRIAL
Hematological Oncology · 2023-06 · 41 (S2) · 881-882
DOI: 10.1002/hon.3196_lba5 ↗Kurz gefasst
Fachartikel in der Zeitschrift Hematological Oncology, online erschienen am 09.06.2023. Verfasst von P. Borchmann und 33 weiteren Autor:innen. Die Arbeit wurde bisher 24-mal zitiert (Crossref).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Borchmann, P., Moccia, A. A., Greil, R., Schneider, G., Hertzberg, M., Schaub, V., Hüttmann, A., Keil, F., Dierlamm, J., Hänel, M., Novak, U., Meissner, J., Zimmermann, A., Mathas, S., Zijlstra, J. M., Fosså, A., Viardot, A., Hertenstein, B., Martin, S., …, & Engert, A. (2023). BRECADD IS NON‐INFERIOR TO EBEACOPP IN PATIENTS WITH ADVANCED STAGE CLASSICAL HODGKIN LYMPHOMA: EFFICACY RESULTS OF THE GHSG PHASE III HD21 TRIAL. Hematological Oncology, 41(S2), 881-882. https://doi.org/10.1002/hon.3196_lba5
Vancouver
Borchmann P, Moccia AA, Greil R, Schneider G, Hertzberg M, Schaub V, et al. BRECADD IS NON‐INFERIOR TO EBEACOPP IN PATIENTS WITH ADVANCED STAGE CLASSICAL HODGKIN LYMPHOMA: EFFICACY RESULTS OF THE GHSG PHASE III HD21 TRIAL. Hematological Oncology. 2023;41(S2):881-882. doi:10.1002/hon.3196_lba5
BibTeX
@article{Borchmann2023,
author = {Borchmann, P. and Moccia, A. A. and Greil, R. and Schneider, G. and Hertzberg, M. and Schaub, V. and Hüttmann, A. and Keil, F. and Dierlamm, J. and Hänel, M. and Novak, U. and Meissner, J. and Zimmermann, A. and Mathas, S. and Zijlstra, J. M. and Fosså, A. and Viardot, A. and Hertenstein, B. and Martin, S. and Giri, P. and Kamper, P. and Molin, D. and Kreissl, S. and Ferdinandus, J. and Fuchs, M. and Rosenwald, A. and Klapper, W. and Eich, H. and Baues, C. and Hallek, M. and Dietlein, M. and Kobe, C. and Diehl, V. and Engert, A.},
title = {BRECADD IS NON‐INFERIOR TO EBEACOPP IN PATIENTS WITH ADVANCED STAGE CLASSICAL HODGKIN LYMPHOMA: EFFICACY RESULTS OF THE GHSG PHASE III HD21 TRIAL},
journal = {Hematological Oncology},
year = {2023},
volume = {41},
number = {S2},
pages = {881--882},
doi = {10.1002/hon.3196_lba5}
}
EUVIMED